Director Spends HKD 32.7M on Insider Share Purchase
Fu Wei, a Non-Executive Director and major shareholder of Genscript Biotech (01952.HK), executed a substantial open-market acquisition of company stock on March 27, 2026. Through a controlled entity, Fu purchased 860,000 ordinary shares for a total consideration of approximately HKD 32.7 million. The transaction was completed at an average price of about HKD 38.12 per share, representing a significant capital injection from a key insider.
Move Signals Strong Conviction in Future Prospects
This insider purchase serves as a strong vote of confidence from a prominent figure within Genscript's leadership. Fu, who also serves as the Honorary Chairman of the Board, stated that the acquisition reflects his firm belief in the company's future prospects and long-term development. Such a sizable on-market purchase by a director is often interpreted by investors as a bullish signal, suggesting that company leadership believes the stock is favorably valued. Fu also indicated he does not rule out further increasing his stake in the company at an appropriate time, market conditions permitting.
